Category:
Paediatric inflammatory bowel disease: a multi-stakeholder perspective to improve development of drugs for children and adolescents
September, 2022
The study aims to find potential advanced treatment options for children with inflammatory bowel disease. A 2-day virtual meeting was held on April 14–15, 2021, for multi-stakeholders (clinical academics, patient community, pharmaceutical companies, and regulators) to discuss their perspectives on paediatric drug development for inflammatory bowel disease.